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Page 3 coronary dilation in hypertensive patients independently of BP lowering. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARB.
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Condensed Abstract
Olmesartan, but not amlodipine, improved coronary endothelial function in hypertensive patients, indicating that angiotensin II receptor blocker has greater beneficial effects on coronary endothelial function independently of blood pressure lowering. 
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Introduction
Hypertension is a major risk factor of coronary artery disease (1) . In hypertensive patients, coronary vasodilator response is impaired (2), which is caused not only by the elevation of blood pressure (BP) but also by inflammation and oxidative stress in the vascular wall induced by angiotensin II (3,4).
Angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) are highly used in the treatment of hypertension. ARB has been demonstrated to reduce inflammation (5) and oxidative stress (4) via directly blocking the action of angiotensin II. Therefore, the effects of antihypertensive drugs on endothelial function may differ between ARB and CCB.
Myocardial blood flow (MBF) could be measured by using oxygen-15 labeled Thus, this study was performed to compare the effects of ARB and CCB on endothelium-dependent coronary dilation in patients with essential hypertension.
Furthermore, the relation between blood biomarkers and coronary endothelial function was also evaluated. 
Materials and Methods
Patients
PET Scans
MBF at rest and during CPT were determined using 15 O-water and PET before and after treatments. All patients refrained from caffeine-containing beverages for at least 24 hours and from smoking for at least 12 hours before the PET study. All PET scans were performed with ECAT EXACT HR+ (Siemens/CTI, Knoxville, Tennessee) by modified methods as previously reported (9). CPT was performed as follows: The patient's right Reconstruction of emission sinograms and quantification of MBF using semiautomatic program were performed according to the methods as previously reported (10).
MBF was corrected against rate pressure product (RPP) to account for individual differences in cardiac work as follow (9); MBF was divided by RPP and multiplied by 7,500, which is the average RPP at rest of healthy controls with age of 50.1±9.7 years.
ΔMBF, an index of coronary endothelial function, was calculated as corrected MBF during CPT minus corrected MBF at rest (11). CVR was calculated by dividing mean BP by MBF to exclude the effects of coronary perfusion pressure as previously reported (11). CVR during CPT was also used as an index of coronary endothelial function (8,11).
ΔCVR was calculated as CVR during CPT minus CVR at rest.
Statistical Analyses
All data were expressed as mean ± SD. Baseline characteristics between groups were compared by an unpaired t-test. Within treatment groups, the changes of corrected MBF and CVR from rest to CPT were compared by a paired t-test. Between-group comparisons with regard to hemodynamic, blood biomarkers, ΔRPP, ΔMBF, and ΔCVR before and after treatment were performed by 2-way ANOVA with repeated measures followed by the Scheffé's test if the interaction was significant. Univariate analysis of the association between serum SOD activity and CVR during CPT was performed with the use of linear regression. A P<0.05 was considered to be statistically significant. 
Results
Study Patients
MBF Response to CPT
The increase of RPP from rest to CPT was comparable before and after treatment between groups (olmesartan: 2,410±1,823 vs. 2,523±1,528 mmHg/min; amlodipine:
2,925±1,298 vs. 2,639±1,504 mmHg/min, P=0.49 by 2-way ANOVA with repeated measures). Before treatment, corrected MBF was significantly decreased from rest to CPT in both groups. After treatment, corrected MBF did not change from rest to CPT in olmesartan group whereas it tended to decrease in amlodipine group (Figure 1 ).
Corrected MBF during CPT was significantly increased after treatment in olmesartan group, but not in amlodipine group (Figure 1 ). The increase of ΔMBF tended to be greater in olmesartan group than in amlodipine group (P=0.09 by 2-way ANOVA with repeated measures; Figure 2 ).
CVR Response to CPT
Before treatment, CVR did not change from rest to CPT in either group. After treatment, CVR significantly decreased from rest to CPT in olmesartan group, but not in
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amlodipine group (Figure 3) . CVR during CPT significantly decreased after treatment in olmesartan group, but not in amlodipine group. The decrease of ΔCVR was significantly greater in olmesartan group than in amlodipine group (P<0.05 by 2-way ANOVA with repeated measures; Figure 4) . ΔCVR significantly decreased after olmesartan, but not after amlodipine (Figure 4 ).
Blood Biochemical Markers
Blood biomarkers including total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, blood sugar, insulin, HOMA-IR, TNF-α, IL-6, and hs-CRP were comparable between groups (Table 3) . Serum SOD tended to increase in olmesartan group compared with amlodipine group (P=0.07 by 2-way ANOVA with repeated measures). There was a significant negative correlation between the changes of serum SOD activity and CVR during CPT in olmesartan group, whereas no such correlation was observed in amlodipine group ( Figure 5) .
Discussion
The present study demonstrated that 12-week treatment of hypertensive patients with olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation despite comparable BP reduction. Serum SOD activity tended to increase only in the olmesartan group. Notably, there was a significant relationship between the improvement of coronary endothelial dysfunction and the increase of serum SOD by
olmesartan.
Previous studies demonstrate that CCB improves the vasodilation of the epicardial coronary arteries in hypertensive patients (12). However, in the case of non-obstructed coronary arteries, MBF is not regulated by the conduit epicardial coronary arteries, but rather by the coronary microcirculation as is the largest part of the resistance of the coronary tree. Therefore, the present study suggested that ARB, but not CCB, might improve the endothelial function in coronary microcirculation, which is most prone to be affected by damaging cardiovascular risk factors such as hypertension (2) .
Consequently, any treatment strategy mostly targeting coronary microcirculation would be expected to prevent early episodes of myocardial ischemia by keeping coronary resistance as low as possible during high flow demand situations. The present study has thus provided a direct evidence to suggest that ARB has such beneficial effects on coronary microcirculation.
Some groups previously reported the similar effects of ACE inhibitors on MBF in response to dipyridamole (13). However, they compared the effects of ACE inhibitor to those by placebo, which did not allow us to comment on any effects beyond BP lowering. In addition, a previous study found a beneficial effect of an ACE inhibitor, lisinopril, but not ARBs, losartan, on MBF response to dipyridamole (14). However, first, not all ARBs have the same effects on coronary microcirculation; i.e. olmesartan seems to have such an effect but not losartan. Second, the present study used the CPT, which is an established stimulus mostly dependent on endothelial function (6,7,11), while the previous study used dipyridamole, which is less endothelium-dependent.
The present study demonstrated that the augmentation of serum SOD by olmesartan might be involved in the improvement of coronary endothelial function. In addition, ARB can directly inhibit angiotensin II-mediated superoxide production (15). These results suggest that the antioxidant effects of olmesartan are specific for this ARB and differ from unspecific effects of vitamin C. More importantly, these effects of olmesartan can explain the contrasting results, in which ARB losartan failed to improve MBF response to dipyridamole (14) whereas olmesartan could exert beneficial effects on coronary microcirculation as seen in the present study.
Study Limitations
First, the present study was not a blinded, randomized study. However, the characteristics of the study patients were well matched between the two groups ( Table   1-3) . Importantly, MBF, CVR, and blood biomarkers were measured and analyzed by another group of investigators who were blinded to the treatment groups. Second, central BP measurement as in the CAFE study (16) , which might affect MBF more effectively than peripheral BP, was not available in the present study. Therefore, a further study is clearly needed to evaluate the relation between the central BP and MBF. ΔMBF from rest to CPT before and after treatment with olmesartan (n=13) and amlodipine (n=13). ΔCVR from rest to CPT before and after treatment with olmesartan (n=13) and amlodipine (n=13). Relationship between the changes of CVR during CPT and serum SOD activity after treatment with olmesartan (n=13; panel A) and amlodipine (n=13; panel B). 
